Back to results
US 2023/0414762 A1Published application
Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
AssigneeThe Johns Hopkins University
InventorsSrikanth Boinapally, IL Minn, Martin G. Pomper
Life of this patent
Estimating the term…
Abstract
A non-radioactive prodrug comprising a PSMA-targeted moiety, a cleavable linker, and an antineoplastic agent capable of selectively killing PSMA-expressing cells and methods of treating a disease or condition associated with PSMA-expressing tumors or cells is disclosed.
Claims31
A compound comprising a PSMA-targeting moiety (T), a cleavable linker (L1), and an antineoplastic agent (A) of formula (I):
- A-L1-T (I).
Dependencies are inferred from the claim text.